Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.02. | OS Therapies gears up for osteosarcoma drug approval | 1 | Investing.com | ||
04.02. | OS Therapies bereitet sich auf die Zulassung eines Osteosarkom-Medikaments vor | 1 | Investing.com Deutsch | ||
31.01. | OS Therapies announces offering of 10.83M shares by selling stockholders | 1 | Seeking Alpha | ||
31.01. | OS Therapies Inc - S-1, General form for registration of securities | - | SEC Filings | ||
29.01. | OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process | 1 | FierceBiotech | ||
OS THERAPIES Aktie jetzt für 0€ handeln | |||||
29.01. | OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up | - | RTTNews | ||
29.01. | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | 109 | Business Wire | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
29.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
15.01. | Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday? | 1 | Benzinga.com | ||
15.01. | OS Therapies' HER2 drug prevented lung cancer from returning in a 3rd of patients | 2 | FierceBiotech | ||
15.01. | Pre-market Movers: Safe & Green Holdings, OS Therapies, Vision Marine Technologies, Giftify, Millennium Group International | 750 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Safe & Green Holdings Corp. (SGBX) is up over 155%... ► Artikel lesen | |
15.01. | OS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trial | 2 | Seeking Alpha | ||
15.01. | OS Therapies-Aktie steigt nach Erfolg in Phase-2b-Studie stark an | 3 | Investing.com Deutsch | ||
15.01. | OS Therapies stock soars on Phase 2b trial success | 2 | Investing.com | ||
14.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
13.01. | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
03.01. | OS Therapies Inc - S-1/A, General form for registration of securities | - | SEC Filings | ||
30.12.24 | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
24.12.24 | OS Therapies prices $6M private placement | 1 | Seeking Alpha | ||
18.11.24 | OS Therapies reports Q3 results | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 68,36 | 0,00 % | Tempus AI's Chefjurist Erik Phelps verkauft Aktien im Wert von 400.960 US-Dollar | ||
SPRINGWORKS THERAPEUTICS | 54,02 | 0,00 % | EQS-Adhoc: Merck KGaA: Merck KGaA bestätigt Gespräche mit Springworks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck KGaA bestätigt Gespräche mit Springworks Therapeutics, Inc. zu möglicher Übernahme
10.02.2025 / 20:06 CET/CEST
Veröffentlichung... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,665 | 0,00 % | Where Recursion Pharmaceuticals Stands With Analysts | ||
VIR BIOTECHNOLOGY | 9,380 | -4,67 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
IMMUNOVANT | 19,520 | -4,36 % | Immunovant Inc.: Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 | Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,310 | 0,00 % | Chefin für Programmentwicklung bei Avidity Biosciences verkauft Aktien im Wert von 188.918 US-Dollar | ||
89BIO | 10,980 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
KAMADA | 8,360 | 0,00 % | Kamada Ltd.: Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB and VARIZIG in Latin America | REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for... ► Artikel lesen | |
BULLFROG AI | 3,350 | 0,00 % | BullFrog AI Holdings, Inc.: BullFrog AI Issues Letter to Stockholders | GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen | |
QIAGEN | 39,020 | +0,05 % | DAX-Check LIVE: Aurubis, Hannover Rück, HelloFresh, Metro, Qiagen, Rational & Co. | Auch wenn bezüglich der zukünftigen Zinspolitik von Donald Trump noch viele Fragen offen bleiben, stabilisierte sich der DAX gestern. Er drehte nach anfänglichen Verlusten ins Plus und schloss schließlich... ► Artikel lesen | |
ARCELLX | 67,00 | +0,04 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,500 | 0,00 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
JANUX THERAPEUTICS | 37,820 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 24,320 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 11,540 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen |